Horizon Kinetics Asset Management LLC Sells 121 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Horizon Kinetics Asset Management LLC lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,759 shares of the biopharmaceutical company’s stock after selling 121 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $759,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. Ashton Thomas Private Wealth LLC acquired a new stake in Alnylam Pharmaceuticals in the second quarter worth about $26,000. Huntington National Bank boosted its holdings in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth about $29,000. Washington Trust Advisors Inc. acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth about $42,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth about $45,000. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Scotiabank raised their price target on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. Wells Fargo & Company raised their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Citigroup raised their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Stock Up 2.5 %

Alnylam Pharmaceuticals stock opened at $250.98 on Tuesday. The stock has a market capitalization of $32.37 billion, a PE ratio of -95.79 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The business has a 50 day simple moving average of $273.13 and a 200-day simple moving average of $238.67. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.15 EPS. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.